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Abstract
Background: High dose estrogens (HDEs) were frequently used as endocrine agents prior to the
introduction of tamoxifen which carries fewer side effects. Due to the development of resistance
to available endocrine agents in almost all women with metastatic breast cancer, interest has
renewed in the use of HDEs as yet another endocrine option that may have activity. We report
our experience with one of the HDEs ("ethinylestradiol" 1 mg daily) in advanced breast cancer
(locally advanced and metastatic) in post-menopausal women who had progressed on multiple
endocrine agents.
Patients and methods: According to a database of advanced breast cancer patients seen in our
Unit since 1998, those who had complete set of information and fulfilled the following criteria were
studied: (1) patients in whom further endocrine therapy was deemed appropriate i.e., patients who
have had clinical benefit with previous endocrine agents or were not fit or unwilling to receive
chemotherapy in the presence of potentially life-threatening visceral metastases; (2) disease was
assessable by UICC criteria; (3) were treated with "ethinylestradiol" until they were withdrawn
from treatment due to adverse events or disease progression.
Results: Twelve patients with a median age of 75.1 years (49.1 – 85 years) were identified. Majority
(N = 8) had bony disease. They had ethinylestradiol as 3rd to 7th line endocrine therapy. One patient
(8%) came off treatment early due to hepato-renal syndrome. Clinical benefit (objective response
or durable stable disease for ≥ 6 months) was seen in 4 patients (33.3%) with a median duration of
response of 10+ (7–36) months. The time to treatment failure was 4 (0.5–36) months.
Conclusion: Yet unreported, high dose "ethinylestradiol" is another viable therapeutic strategy in
heavily pre-treated patients when further endocrine therapy is deemed appropriate. Although it
tends to carry more side effects, they may not be comparable to those of other HDEs (such as
diethylstilbestrol) or chemotherapy.
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Background
High dose estrogens (HDEs) were the alternative modality
of endocrine therapy in advanced breast cancer besides
surgical ablation of ovaries before the advent of modern
endocrine agents. The discovery of tamoxifen relegated
use of HDEs as first line endocrine therapy to history.
In almost all women with advanced breast cancer, dura-
tion of activity is shortened by development of resistance
to endocrine agents. Interest, therefore, has renewed in
the usage of HDEs towards the end of sequencing therapy
after resistance to multiple endocrine agents. Usage of
diethylstilboestrol (DES) in these patients heavily pre-
treated with endocrine agents was reported recently by
Lonning et al [1]. Yet unreported in literature [2], we dem-
onstrate from our dataset that reasonable clinical efficacy
and better tolerability can be obtained with high dose
"ethinylestradiol" in these heavily pre-treated patients.
Patients and methods
Patients
Case notes of patients with advanced breast cancer (meta-
static and locally advanced) since 1998 fulfilling the fol-
lowing criteria were reviewed:
• Estrogen receptor (ER) positive disease
￿ With disease assessable by UICC criteria [3]
￿ Patients have had previous endocrine therapies
￿ In whom further endocrine therapy was deemed appro-
priate i.e., those patients who have had clinical benefit
with previous endocrine agents and were not fit or unwill-
ing to receive chemotherapy in the presence of potentially
life-threatening visceral metastases.
Methods
Patients were treated with Ethinylestradiol (1 mg daily)
until they were withdrawn from treatment either due to
adverse events or disease progression.
Assessment of therapeutic response was made as per UICC
criteria. Assessable lesions were deemed to have shown
clinical benefit (CB) when they either had objective
response in the form of complete response (CR) or partial
response (PR); or had stable disease (SD) for ≥ 6 months
[4,5]. Time to treatment failure (TTF) is the duration of
treatment in months of patients who have failed on treat-
ment including those with adverse events (not including
patient still on treatment)
Time to progression (TTP) is the duration of treatment in
months of patients who have progressed (not including
patient still on treatment).
Duration of Response (DOR) is the duration of treatment
in months of patients who have had CB.
Results
Twelve patients with a median age of 75.1 years (49.1 –
85.0 years) were identified as shown in Table 1. Out of all
these post-menopausal women, 3 patients had locally
advanced breast cancer while the remaining 9 had meta-
static breast cancer. Eight of the 9 patients with metastatic
breast cancer had bony disease with bone only disease in
4 of them.
Table 1: Patient characteristics and tumor response to ethinylestradiol
Patient 
Number
Age at Rx (years) Sites of disease Previous endocrine 
therapies
Response at 6 
months
Duration of 
Treatment (months)
1 85 Local T, M, A, E, T PR 7+
2 57 Local T+G, M, Agt, Fr+G, T, A PR 8
3 84 Bone, liver, mediastinal 
nodes
T, M, A, E PR 12
47 6 L o c a l T ,  A ,  M SD 36
5 80 Local, bone, pleura, 
ascites
T, F, A, M, E PD 3
6 49 Bone T+G, A+G, M, E+G PD 6
7 79 Local, bone, lung T, M, Agt, MPA, Fr PD 2
8 74 Bone M, E, T PD 3
9 74 Bone T, A, M, E PD 2
10 84 Lung, pleura A, M, E, F PD 4
11 64 Bone E, Lt, T PD 6
12 64 Bone, liver A, M N/A* 0.5
Rx = Treatment; T = Tamoxifen; A = Anastrozole; E = Exemestane; M = Megestrol acetate; Lt = Letrozole; F = Fulvestrant; Agt = 
Aminoglutethimide; Fr = Formestane; MPA = Medroxyprogesterone acetate; G = Goserelin; N/A* = Not applicable as the patient was withdrawn 
due to side-effects.World Journal of Surgical Oncology 2006, 4:44 http://www.wjso.com/content/4/1/44
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The patients received ethinylestradiol as 3rd to 7th line
endocrine therapy for advanced breast cancer. Four (no.1,
2, 3, 4) out of 12 patients had CB (33.3%) with a median
DOR of 10 + (7 to 36) months. Objective response in the
form of PR was seen in 3 (25%) patients (no. 1, 2, 3) while
one patient (no. 4) had SD for 36 months.
The median TTP of the patients was 5 (2 to 36) months.
One patient (no. 1) is still on treatment at 7+ months.
Another patient (no. 12) came off treatment early due to
hepato-renal syndrome. Therefore, the median TTF is 4
(0.5 to 36) months. Efficacy of ethinylestradiol is demon-
strated in Table 1.
Apart from the patient (no 12) who came off treatment in
2 weeks due to hepato-renal syndrome, none of the other
patients had grossly deranged Liver Function Tests (LFTs)
secondary to ethinylestradiol or any other reported side-
effects. The deranged LFTs in this patient improved as
soon as ethinylestradiol was stopped as shown in Figure 1.
Discussion
Efficacy
The first clinical trial of tamoxifen in post-menopausal
women with advanced breast cancer was reported in 1971
by Cole et al [6]. They reported similar efficacy of
tamoxifen compared with efficacy of DES or androgen in
another trial. In a randomized clinical trial comparing
nafoxidine (an erstwhile non-steroidal antagonist) and
ethinylestradiol back in 1975, Heuson et al[7] demon-
strated objective remission in 14% of 49 women on ethi-
nylestradiol compared with 31% with nafoxidine.
Massidda et al[8] reported objective remission in 50 % of
patients treated with estrogens.
Beex et al[9] reported objective remission in 31% of ethi-
nylestradiol treated patients compared with 33% of
tamoxifen treated patients in a randomized study of 63
post-menopausal women with advanced breast cancer.
The median duration of response and median survival
times of ethinylestradiol and tamoxifen were similar: 12
months versus 11 months and 31 months versus 25
months respectively.
A randomized clinical trial of 143 women by Ingle et
al[10] compared tamoxifen with DES in post-menopausal
patients to determine their relative efficacy and toxicity.
99 women had received no prior systemic therapy and 44
had received previous chemotherapy. The objective
response rate was higher in patients who received DES
(41%) than in those who received tamoxifen (33%),
though the difference was not significant (P = 0.37). In
patients who had had no prior systemic therapy, the
response rates with DES and tamoxifen were 44% and
38%, respectively (P = 0.55), and in those who had had
previous chemotherapy, 32% vs. 23% respectively (P =
0.50). In addition, there was no significant difference
between the two treatment groups on analysis of the time
to treatment failure (medians: DES, 142 days; tamoxifen,
171 days). A recent update of this trial [11] reported sig-
nificant (P = 0.039) survival advantage of patients on DES
over tamoxifen (median survival of 3.0 years versus 2.4
years).
Therefore, most of the studies had proved beyond doubt
similar efficacy of HDEs, if not greater when compared
with early anti-estrogens including tamoxifen, there being
no statistically significant difference. As because
tamoxifen had a favourable side-effect profile, it was the
preferred agent to estrogens [12,13].
An assorted collection of endocrine agents such as aro-
matase inhibitors, progestogens, pure anti-estrogens have
since been in vogue. The development of resistance to all
these agents though has proved to be the Achilles' heel of
the whole gamut of endocrine therapy. Even if one agent
is used after another as is the practice in sequencing ther-
apy, each agent yields to the development of resistance.
Therefore, the need for further endocrine therapy has
rekindled interest in the use of HDEs as yet another endo-
crine option with possible activity.
The interest in the usage of HDEs after heavy pre-treat-
ment with anti-estrogens comes from several in-vitro and
Changes in clinical chemistry on ethinylestradiol in patient  (no. 12) with hepato-renal syndrome Figure 1
Changes in clinical chemistry on ethinylestradiol in patient 
(no. 12) with hepato-renal syndrome. ALT (Alanine amino-
transferase); Bilirubin = Total Bilirubin; Eg = Ethinylestradiol; 
Before Eg = before commencement of Eg; After Eg = after 
withdrawal of Eg V* = Reference Ranges for values: Urea = 
1.0–6.5 mmol/L; Creatinine = 60–120 μmol/L; ALT = 5–40 
U/L; Total Bilirubin = 0–17 μmol/L.
0
50
100
150
200
250
300
1 week 
Before Eg
2 weeks 
On Eg
1 week
After Eg
3 weeks
After Eg
Time interval
V
*
Urea Creatinine ALT Bilirubin
6 weeks
After EgWorld Journal of Surgical Oncology 2006, 4:44 http://www.wjso.com/content/4/1/44
Page 4 of 5
(page number not for citation purposes)
animal studies. Masamura et al [14] showed in MCF-7
cells that long-term estrogen deprivation (akin to usage of
anti-estrogens in humans) caused cells to develop estro-
gen hypersensitivity. Though cells replicated at a concen-
tration of 10-15 to 10-14 M/L of estradiol, at a concentration
of 10-10 M/L, replication was inhibited. Osipo et a l [15]
demonstrated apoptosis in long-term estrogen deprived,
aromatase resistant breast cancer cell model (MCF-7:5C)
at a concentration of 10-11 M/L or more of estradiol. Sim-
ilarly, in tamoxifen treated athymic mice serially trans-
planted with MCF-7TAM and MT2 tumor lines, Yao et al
[16] showed that tumor regressed in response to estradiol.
Later, both lines regrew on estradiol but the lines were
then responsive to tamoxifen again.
The CB rate of 33% in our study is similar to published lit-
erature. However, our patients were not endocrine naïve
patients as in previous studies. They have had at least 2
previous estrogen depriving therapies for advanced breast
cancer and were at the end of the sequence of endocrine
treatment lines. Lonning et al[1] recently demonstrated a
high response rate to DES given at least after 2 (median of
4) previous estrogen depriving endocrine therapies. The
authors demonstrated a CB rate of 38% in 32 patients and
therefore, surmised that the estrogens administered in
high doses represent a valuable alternative to chemother-
apy in selected patients. Further data on HDEs may be
available from a phase II study by WJ Gradishar at Robert
Lurie Cancer Center (in collaboration with National Can-
cer Institute), Chicago, USA which commenced in August
2005 to determine clinical response and side-effects of
high dose esterified estrogens (Menest™) in post-meno-
pausal women with metastatic breast cancer that has
failed previous hormone therapy.
Tolerability
Side-effects are commoner with HDEs compared with
anti-estrogens resulting in higher rate of withdrawal from
therapy but they still appear to be more favorable than
chemotherapeutic agents. Massidda et al[8] reported side-
effects mainly as cholestatic liver abnormality. In the
study by Beex et al[9], 2 patients were withdrawn because
of hepatic impairment.
Lonning et al[1] reported a withdrawal rate of 18% (6 out
of 32 patients) owing to side-effects. Similar toxicity rate
was reported in patients receiving DES in study by Ingle et
al[10]; 9 of 74 patients (12%) discontinued therapy solely
because of adverse reactions.
One (= 8.3%) patient in our study was withdrawn due to
the development of hepato-renal syndrome within 2
weeks of commencement of treatment. The derangement
of hepatic function, however, reverted back to normality
within 2 weeks of stopping treatment in spite of the fact
that this patient had pre-existing liver metastasis. As the
LFTs were normal in this patient before the commence-
ment of therapy, early (within 2 weeks) and regular test-
ing of LFTs may be imperative in patients treated with
ethinylestradiol. The withdrawal rate of 8.3% is, however,
less than 18% seen with DES [1] in similar heavily pre-
treated patient group. There were no reported side-effects
in the remaining patients.
Most of the side-effects attributable to estrogens are, how-
ever, due to the high clinical doses including the patient
with hepato-renal syndrome in our study group. Osipo et
al[15] and Jordan et al[17] have recently showed in their
in-vivo study in athymic mice involving MCF-7 breast
cancer cell lines that complete reversal of resistance to
tamoxifen can be achieved with the use of low dose estro-
gen therapy. Based on their results, they suggest using an
alternating treatment regimen, cycling antiestrogen with
estrogen therapy to avoid drug-resistance.
In a clinical series by Pellegrini et al [18] in 1981, 19
patients unresponsive to conventional chemotherapy and
chemo-hormone therapy were treated with an alternating
sequential schedule of ethinylestradiol and medroxypro-
gesterone on the basis of correlations between hormones
and estrogen and progestin receptors. Six patients had par-
tial or complete remission and 5 others had minor
responses.
Conclusion
The resistance to endocrine therapy is evident in all lines
of endocrine therapy with any of the available endocrine
agents. Therefore, a virtual endpoint seems to appear
wherein these patients are at the end of sequencing ther-
apy with these endocrine agents. If these patients have had
CB with endocrine therapy and if they have disease not
suitable for chemotherapeutic agents or because the
patients are not fit or unwilling; use of high dose ethi-
nylestradiol may be beneficial. The side-effects are higher
than existing endocrine agents but less when compared
with chemotherapy. It perhaps may be useful to utilise
high dose ethinylestradiol in the sequential endocrine
therapy alternating with other endocrine agents although
clinical efficacy of low dose estrogens in this context
remains to be evaluated.
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